CCL28-induced RARĪ² expression inhibits oral squamous cell ... - PMC
The retinoic acid receptor beta 2 (RARĪ²2) is a member of the nuclear receptor superfamily that plays a vital role in regulating cell growth, differentiation, and programmed cell death (apoptosis). In many human cancers, the expression of this gene is lost or significantly reduced, which is a key step in the development of tumors. Understanding the mechanisms that silence RARĪ²2 is essential for developing new strategies to reactivate it and halt cancer progression. J2 rar
RARĪ²2 stands as a critical guardian against the uncontrolled cell growth that defines cancer. While its silencing through DNA methylation and histone modification is a hallmark of many tumors, the reversible nature of these changes offers a unique therapeutic window. Continued research into the molecular triggers of RARĪ²2 may lead to more effective treatments that leverage the bodyās own regulatory systems to combat disease. CCL28-induced RARĪ² expression inhibits oral squamous cell
While "J2" and "RAR" appear in several contexts, your request most likely refers to the isoform, which is a critical tumor suppressor gene in cancer research. Continued research into the molecular triggers of RARĪ²2
The following essay outlines the biological significance of the , focusing on its role in cancer suppression, the mechanisms behind its silencing, and its potential as a therapeutic target. The Role and Silencing of RARĪ²2 in Human Cancer
One of the most common reasons RARĪ²2 stops working is epigenetic silencing through a process called DNA methylation. In many malignancies, such as lung and head and neck cancers, the promoter region of the RARĪ²2 geneāessentially its "on switch"ābecomes chemically modified by methyl groups. This physical blockage prevents the cell's machinery from reading the gene. Furthermore, enzymes known as histone deacetylases (HDACs) help lock the DNA into a tightly coiled, inactive state, further ensuring that the gene remains silent.